DGAP-News: Glycotope GmbH: Glycotope names Henner Kollenberg as Managing Director and Chief Financial Officer

DGAP-News: Glycotope GmbH / Key word(s): Change of Personnel
Glycotope GmbH: Glycotope names Henner Kollenberg as Managing Director
and Chief Financial Officer

20.03.2014 / 09:30

---------------------------------------------------------------------

Berlin, Germany, March 20, 2014 - Glycotope GmbH, one of the leading
companies in glycobiology, expands its management team and named Henner
Kollenberg as Managing Director and Chief Financial Officer (CFO) as of
March 2014.

Mr. Kollenberg brings more than 16 years of experience in general
management, strategic planning and finance to the Company. Previously, he
was Investment Director at Eckert Life Science Accelerator GmbH (ELSA).
Before this, he worked as Managing Partner at Qonsult Group, a European
consulting group, where he built up the Merger & Acquisitions and Private
Equity units with a focus on technology-driven investments. For leading
private equity funds Mr. Kollenberg advised portfolio companies through the
entire investment life cycle, including deal sourcing, performance
improvement and value creation, until the exit. He started his career in
the corporate strategy department of Stinnes AG, one of Europe's largest
freight transportation and logistics providers. Mr. Kollenberg studied
Economics at the University of Bonn (Diplom-Volkswirt) and earned a
Master's degree in Law & Economics (EMLE) from Stockholm University.

"Mr. Kollenberg has an exceptional track record in financing and managing
fast-growing and dynamic companies with valuable experience in the M&A
field and this expansion of the management team is an important next step
in developing our company," said Dr. Steffen Goletz, CEO, CSO and founder
of Glycotope. "His understanding and knowledge of general management,
planning and finance will be particularly important at this time, when
Glycotope is accelerating its growth through a broad portfolio of drug
candidates in later stage clinical development," added Dr. Franzpeter
Bracht, who held the CFO function next to his function as COO.

"I am very pleased to join Glycotope at this exciting point in its
journey," said Henner Kollenberg. "The Company has evolved into one of
Germany's largest independent biotech companies and I am very much looking
forward to embarking on its next phase of growth and joining this proven
and dynamic management team."
  
About Glycotope

Glycotope specializes in the glycosylation of proteins and is one of
Germany's largest independent biotech companies. Glycotope has a broad
portfolio of drugs in clinical development, including the new cancer drugs,
PankoMab-GEX(TM) and CetuGEX(TM), both in Phase IIb trials, and
TrasGEX(TM), which has successfully completed its Ph I/IIa trial, as well
as its improved fertility hormone, FSH-GEX(TM), which is expected to begin
two Phase III clinical trials in 2014. In addition, the Company owns
various antibody and non-antibody biopharmaceutical candidates in
preclinical development. All products were glycooptimized, fully human
glycosylated and produced with exceptional quality, reproducibility and
yields using the validated GlycoExpress(TM) (GEX(TM)) technology. This
innovative technology enables Glycotope to increase the effectiveness,
tolerability and affordability of a large number of drugs and expands their
patient populations and indications.

Founded in 2001 on the Campus of the Max-Delbrück-Center for Molecular
Medicine in Berlin-Buch, Glycotope now has more than 180 employees at two
locations in Berlin and Heidelberg and covers the entire workflow from
discovery, molecule optimization, clone and process development,
preclinical and clinical drug development including GMP production. The
Company's investors include Munich-based Jossa Arznei GmbH (Strüngmann
Group) and ELSA GmbH (Eckert Life Science Accelerator) in Berlin, which
have provided total financing in excess of EUR 130 million.

Contact:

Glycotope GmbH
Dr. Franzpeter Bracht, COO
Robert-Roessle-Str. 10, D-13125 Berlin, Germany
Phone: +49-(0)30 94 89-2600
Fax: +49-(0)30 94 89-2609
Email: franzpeter.bracht@glycotope.com
Website: www.glycotope.com


End of Corporate News

---------------------------------------------------------------------

20.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


258519 20.03.2014